Effects of Iron Supplementation on Erythropoietic Response in Patients with Cancer-Associated Anemia Treated by Means of Erythropoietic Stimulating Agents
ISRN Hematology · 2011
DOI: 10.5402/2011/108397 ↗Kurz gefasst
Fachartikel in der Zeitschrift ISRN Hematology, 2011. Verfasst von Torbjörn Karlsson. Beteiligte Einrichtung: Department of Hematology, Uppsala University Hospital, 751 85 Uppsala, Sweden. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
During the past decade, intravenous iron supplementation to ESA (erythropoiesis-stimulating agent) therapy has emerged as an option to augment hemoglobin response in anemic cancer patients. In this paper, the results of seven published randomized clinical trials assessing the role of iron supplementation to ESA therapy in the hematology/oncology setting will be discussed. The pathogenetic mechanisms behind functional iron deficiency, a major reason for ESA hyporesponsiveness in cancer, will also be described.
Autor:innen und Institutionen
- Department of Hematology, Uppsala University Hospital, 751 85 Uppsala, Sweden.
Zitieren
APA
Karlsson, T. (2011). Effects of Iron Supplementation on Erythropoietic Response in Patients with Cancer-Associated Anemia Treated by Means of Erythropoietic Stimulating Agents. ISRN Hematology. https://doi.org/10.5402/2011/108397
Vancouver
Karlsson T. Effects of Iron Supplementation on Erythropoietic Response in Patients with Cancer-Associated Anemia Treated by Means of Erythropoietic Stimulating Agents. ISRN Hematology. 2011. doi:10.5402/2011/108397
BibTeX
@article{Karlsson2011,
author = {Karlsson, Torbjörn},
title = {Effects of Iron Supplementation on Erythropoietic Response in Patients with Cancer-Associated Anemia Treated by Means of Erythropoietic Stimulating Agents},
journal = {ISRN Hematology},
year = {2011},
doi = {10.5402/2011/108397}
}
EUVIMED